Avoro Capital Advisors LLC
Q4 2019 13F-HR Holdings
Net value change ($000)
—
New positions
29
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMMUNOMEDICS INC | 518,420 | — |
| Mirati Therapeutics, Inc. | 496,137 | — |
| ASND | 259,459 | — |
| IOVA | 244,305 | — |
| SRPT | 227,110 | — |
| CONSTELLATION PHARMACEUTICALS INC | 171,952 | — |
| BMRN | 169,100 | — |
| ARGX | 150,327 | — |
| Horizon Therapeutics Public Ltd Co | 144,800 | — |
| QURE | 121,822 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
5,160
(0.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|